Evolus, Inc.
EOLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001570562
In the last 90 days, Evolus, Inc. insiders filed 0 open-market purchases and 1 sale; 158 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Evolus, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 137 | 151 | +14 |
| Shares | 41.4M | 45.5M | +4.09M (+9.9%) |
| Value | $378.8M | $479.6M | +$100.7M (+26.6%) |
New holders (28)
Institutions that held Evolus, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (14)
Institutions that held Evolus, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| First Manhattan Co | 2,287,538 | $20.9M |
| Soleus Capital Management, L.P. | 2,078,000 | $19.0M |
| Prosight Management, LP | 126,982 | $1.16M |
| Tudor Investment Corp Et Al | 56,802 | $519.2K |
| Black Swift Group, LLC | 51,000 | $466.1K |
| Walleye Trading LLC | 24,754 | $226.3K |
| Verition Fund Management LLC | 19,118 | $174.7K |
| Simplex Trading, LLC | 12,775 | $116.0K |
| Janney Montgomery Scott LLC | 11,600 | $106.0K |
| Cetera Advisors LLC | 11,477 | $104.9K |
| Gsa Capital Partners LLP | 11,026 | $101.0K |
| Nebula Research & Development LLC | 10,475 | $95.7K |
| Bank of Montreal | 2,616 | $24.7K |
| Quadrant Capital Group LLC | 228 | $2.08K |